Bailard’s Avidity Biosciences RNAM Stock Holding History

Bailard’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,900	Closed	-$409K	–	811
2024 Q3	$409K	Hold	8,900	–	–	0.01%	502
2024 Q2	$364K	Hold	8,900	–	–	0.01%	514
2024 Q1	$227K	Buy	+8,900	New	+$139K	0.01%	657

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bailard's RNAM Position: Q4 2024 in Review

Bailard sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 8,900 shares — an estimated $409K sold.

Bailard first reported a position in RNAM in Q1 2024 and held it in 3 quarters. The position peaked at $409K in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

Bailard reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
Bailard sold 8,900 Avidity Biosciences shares in Q4 2024, an estimated $409K.
Bailard first reported a position in Avidity Biosciences in Q1 2024 and held it in 3 quarters.
Bailard's Avidity Biosciences position peaked at $409K in Q3 2024.
236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Bailard's 13F filing for Q4 2024, filed 5 Feb 2025.